Do HMG-CoA reductase inhibitors improve kidney function? The saga continues

被引：9
作者：
Campese, Vito M. [1 ]
Ku, Elaine [1 ]
Bigazzi, Roberto [1 ]
Bianchi, Stefano [1 ]
机构：
[1] Univ So Calif, Keck Sch Med, Div Nephrol, Los Angeles, CA 90033 USA
来源：
JOURNAL OF NEPHROLOGY | 2011年 / 24卷 / 05期
关键词：
Chronic kidney disease; Proteinuria; Statins; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; RENAL-FUNCTION; ROSUVASTATIN; ATORVASTATIN; PROGRESSION; DYSLIPIDEMIA; EFFICACY; STATINS; WOMEN;
D O I：
10.5301/jn.5000024
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Several reviews have addressed the role of dyslipidemia in renal injury and the potential renal protective effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Experimental evidence in animals strongly supports the concept that statins may be renal protective. However, data in humans are scanty and contradictory. A recent controlled study using rosuvastatin has cast some doubts on the renal protective effect of this drug. This article reviews the available evidence pro and con the renal protective effects of statins in human subjects.
引用
收藏
页码：550 / 553
页数：4
相关论文
共 50 条
  • [31] Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy
    Chang, JT
    Staffa, JA
    Parks, M
    Green, L
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (07) : 417 - 426
  • [32] HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis
    Mermis, Joel D.
    Simpson, Steven Q.
    CURRENT INFECTIOUS DISEASE REPORTS, 2012, 14 (05) : 484 - 492
  • [33] HMG-CoA reductase inhibitors and P-glycoprotein modulation
    Bogman, K
    Peyer, AK
    Török, M
    Küsters, E
    Drewe, J
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (06) : 1183 - 1192
  • [34] MTD-CoMSIA modelling of HMG-CoA reductase inhibitors
    Duda-Seiman, Daniel M.
    Avram, Speranta
    Mancas, Silvia
    Careja, Valentin
    Duda-Seiman, Corina
    Putz, Mihai V.
    Ciubotariu, Dan
    JOURNAL OF THE SERBIAN CHEMICAL SOCIETY, 2011, 76 (01) : 85 - 99
  • [35] HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction
    Riahi, S
    Christensen, JH
    Toft, E
    Skou, HA
    Schmidt, EB
    PHARMACOLOGICAL RESEARCH, 2002, 45 (06) : 479 - 483
  • [36] Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors
    Lippi, Giuseppe
    Favaloro, Emmanuel J.
    Sanchis-Gomar, Fabian
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (05) : 515 - 532
  • [37] HMG-CoA Reductase Inhibitors and Risk of Atrial Fibrillation/Flutter among Patients with and without Chronic Kidney Disease
    Lin, Jou Wei
    Chang, Chia-Hsuin
    Lai, Mei-Shu
    CIRCULATION, 2012, 126 (21)
  • [38] The HMG-CoA reductase inhibitors - New safety concerns?
    不详
    Drugs & Therapy Perspectives, 2001, 17 (24) : 11 - 15
  • [39] Renal tubular toxicity of HMG-CoA reductase inhibitors
    van Zyl-Smit, R
    Firth, JC
    Duffield, M
    Marais, AD
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (12) : 3176 - 3179
  • [40] Atorvastatin: A step ahead for HMG-CoA reductase inhibitors
    Black, DM
    PERFUSION, 1996, 9 (04): : 140 - 142
12345